In a major first for the stem cell and regenerative medicine fields, a patient in Japan today received a pioneering transplant of a retinal pigmented epithelial (RPE) sheet made from induced pluripotent stem (iPS) cells, also known by the acronym IPSC. This is the first ever iPS cell-based transplant into a human. The patient is […]
Landmark: patient receives first ever iPS cell based transplant Read More »
Some diverse new stem cell papers worth a peek this weekend? Direct reprogramming hits crest: Generation of Multipotent Induced Neural Crest by Direct Reprogramming of Human Postnatal Fibroblasts with a Single Transcription Factor, Cell Stem Cell Hormone receptors in prostate cancer cells versus stem cells: Concise Review: Androgen Receptor Differential Roles in Stem/Progenitor Cells Including Prostate, Embryonic, Stromal,
5 new cool stem cell papers worth a look for weekend reading Read More »
The BioTime subsidiary, Asterias, has received FDA approval for a combined Phase I/IIa clinical trial of OPC1 for treating spinal cord injury. BioTime (BTX) and Asterias (ASTY) have picked up the portfolio of the former Geron clinical trial using oligodendrocyte precursor cells (OPC). Asterias also acquired a second element from Geron in the form of a lung
Interview with Jane Lebkowski on Asterias FDA-approved Stem Cell Trial Read More »
Type 1 Diabetes is a huge global problem. Where are the solutions that would compliment or replace insulin therapy for diabetics? There haven’t been too many that have gotten very far, which makes the news of a potential stem cell-based therapy moving along in the pipeline all the more exciting. ViaCyte (see more posts here,
Great News: FDA Nod For ViaCyte IND of Diabetes Stem Cell-Based Product Read More »
This post is a tribute to the late Dr. Yoshiki Sasai (笹井芳樹). If you would like your name added to this tribute please let me know. You are also welcome to add your own tributes in the comments. In an era when the emerging field of regenerative medicine is just beginning to take wing, we
Stem Cell Community Tribute to Yoshiki Sasai (笹井芳樹) Read More »
What have been some recent stem cell and/or regenerative medicine papers that are worth some extra thought and reading? There have been some cool ones. Note, for fun you can fast forward ahead to 2020 to see some of the recommended reads there. There was of course the very important Mitalipov group paper comparing NT
Some cool recent stem cell papers: recommended reading Read More »
Just how good are human embryonic stem (ES) cells made by therapeutic cloning via nuclear transfer, with the successful technique first reported by the lab of Shoukhrat Mitalipov at OHSU last year? How do they compare to induced pluripotent stem (iPS) cells or traditional ES cells made from IVF embryos? A new paper in Nature directly tackles these
Review of Mitalipov Nature paper: cloned ES cells vs iPS cells Read More »
It was great being a postdoc in Bob Eisenman’s Lab at the Hutch in Seattle with colleagues like fellow postdoc Shawn Cowley. I loved it. Bob is a great mentor (see more on my experience there here) and the scientific interactions in the lab were wonderful. It’s been fun and interesting to follow the work
Cool paper by Shawn Cowley Lab on the role of HDACs in ES cells Read More »
A new patent has been awarded to James Sherley for a very unusual method claimed for making induced pluripotent stem (iPS) cells. The patent, No. 8,759,098, claims that a single non-genetic chemical agent, xanthine, can by itself reprogram adult stem cells (ASC) into iPS cells (aka iPSCs; see image they released at left). Surprising patent, huh? Another
Sherley patent for reprogramming method like STAP cells Read More »
There is more good news from leading stem cell biotech Advanced Cell Technology (ACT) on preclinical rodent studies using stem cells to treat mice with an MS-like condition. They published a new paper in the journal Stem Cell Reports entitled “Human ESC-Derived MSCs Outperform Bone Marrow MSCs in the Treatment of an EAE Model of
Advanced Cell Technology (ACT) Revs Up Pre-Clinical Studies for MS Read More »